Formosa Pharmaceuticals, Inc.
Formosa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in developing drug candidates for ophthalmology, oncology, and anti-infectives in Taiwan. It is involved in developing APP13007 that is in Phase III clinical trial for the treatment of post-operative pain and inflammatory eye conditions; TSY-110, an antibody-drug conjugate; and TSY-0210, an antibiotic for drug resi… Read more
Formosa Pharmaceuticals, Inc. (6838) - Total Liabilities
Latest total liabilities as of September 2025: NT$595.70 Million TWD
Based on the latest financial reports, Formosa Pharmaceuticals, Inc. (6838) has total liabilities worth NT$595.70 Million TWD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Formosa Pharmaceuticals, Inc. - Total Liabilities Trend (2021–2024)
This chart illustrates how Formosa Pharmaceuticals, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Formosa Pharmaceuticals, Inc. Competitors by Total Liabilities
The table below lists competitors of Formosa Pharmaceuticals, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nicolas Correa SA
MC:NEA
|
Spain | €57.54 Million |
|
Samsung Pharm
KO:001360
|
Korea | ₩44.04 Billion |
|
Komelon Corporation
KQ:049430
|
Korea | ₩5.60 Billion |
|
Bharat Rasayan Limited
NSE:BHARATRAS
|
India | ₹2.59 Billion |
|
Nelly Group AB
ST:NELLY
|
Sweden | Skr583.30 Million |
|
DocGo Inc
NASDAQ:DCGO
|
USA | $93.12 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down Formosa Pharmaceuticals, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.57 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Formosa Pharmaceuticals, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Formosa Pharmaceuticals, Inc. (2021–2024)
The table below shows the annual total liabilities of Formosa Pharmaceuticals, Inc. from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$563.70 Million | -3.84% |
| 2023-12-31 | NT$586.21 Million | +42.80% |
| 2022-12-31 | NT$410.51 Million | +38.93% |
| 2021-12-31 | NT$295.48 Million | -- |